Listings
Bio Green Med gets Nasdaq bid price notice ahead of a vote that would leave holders under 1%
Nasdaq gave the former Cyclacel until April 27, 2027 to get back above $1.00. The company points to a reverse split tied to a $2 billion share deal with a Malaysian waste firm, which goes to a vote on November 19.

Bio Green Med Solution, the former Cyclacel Pharmaceuticals, told investors on November 4, 2026 that Nasdaq has flagged its common stock for trading below the $1.00 minimum bid price. The filing was signed by Chief Executive Officer and Executive Director Datuk Dr. Doris Wong Sing Ee. The remedy it points to is a reverse split tied to a pending deal with a Malaysian clinical waste company, and that deal would leave today's holders with less than 1% of the company. The stock has already been through two reverse splits since May 2025. In our reading, the question for holders is whose listing is being saved. Nov 4 filing
What Nasdaq said
The Nasdaq Stock Market LLC wrote to the company on October 29, 2026. It said the closing bid price had been below the $1.00 minimum required by Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. Under Listing Rule 5810(c)(3)(A), the company has until April 27, 2027 to comply. It gets back into compliance if the bid price closes at or above $1.00 for at least 10 consecutive business days before then. If it does not, and no extension is granted, Nasdaq will give notice of delisting from The Nasdaq Capital Market, which the company can appeal to a hearings panel. Trading continues for now. Nov 4 filing
This is not the company's first listing problem this year. Its 6% Convertible Exchangeable Preferred Stock (BGMSP) fell short of Nasdaq's $1 million market value requirement for publicly held shares. The company chose not to appeal, trading in the preferred was suspended on March 23, 2026, and a Form 25-NSE removed it from Nasdaq. March 13 filing, 10-Q
The split, and the deal behind it
On June 4, 2026, the company signed a Business Combination Agreement with Future NRG Sdn. Bhd. (FNRG), a Malaysian private limited company, and its shareholders. They will swap all their FNRG shares for Bio Green Med common stock. The Form S-4, filed on June 26 and declared effective on October 8, includes a proposal for a reverse split at a ratio the board will pick between 1:4 and 1:16. The company says it will consider alternatives, including "a potential reverse stock split, as part of the closing of the Transaction." It also says there can be no assurance stockholders will approve the split or that it will regain compliance. Nov 4 filing
The proxy statement sets the vote at a virtual special meeting at 12:30 p.m. Eastern Time on November 19, 2026. The deal is priced at an Aggregate Transaction Consideration Value of $2,000,000,000, divided by the 30-day volume-weighted average price before closing. On that basis, the company estimates that FNRG's selling shareholders will own more than 99.0% of the common stock, leaving current holders with less than 1.0%. Another proposal would raise the authorized common stock to 3,000,000,000 shares. The stock closed at $0.83 on June 15, 2026. The proxy warns the company may pay more than FNRG's fair market value, since FNRG has no public market and the share percentage was negotiated. Proxy statement
FNRG treats clinical waste with ozone rather than incineration at a plant that can handle 10 metric tons a day. The proxy says one customer accounted for about 70% of its 2025 revenue, and that contract was renewed on May 1, 2026. FNRG is also a defendant in two suits that AHT Syngas Technology NV brought in the Shah Alam High Court, with a trial scheduled for the second half of 2026. Its current liabilities are almost entirely a provision for that litigation, with no committed credit facility behind it. Proxy statement
A small business with little cash
Cyclacel closed the purchase of Fitters Sdn. Bhd., a Malaysian fire safety business, on September 12, 2025 and took the Bio Green Med name. Revenue for the six months to June 30, 2026 was $1.1 million, all from fire safety products, and the net loss was $0.6 million. Cash and cash equivalents were $3.8 million, which management says will last into the first quarter of 2027. The 10-Q states there is substantial doubt about the company's ability to continue as a going concern. The accumulated deficit was $455.0 million. There were 6,622,794 common shares outstanding on August 11, 2026, after reverse splits of 1-for-16 on May 12, 2025 and 1-for-15 on July 7, 2025. 10-Q
Its latest equity raise was small: 1,103,338 shares sold in a June 10, 2026 private placement at $0.72 a share, for gross proceeds of $794,403, now registered for resale. S-3
What comes next
The results of the November 19 meeting will show whether holders approve the deal, the share increase and the split range. After that, the question is whether the bid price can close at or above $1.00 for 10 straight business days before April 27, 2027. The company lists its ability to meet Nasdaq's listing standards before and after the transaction among its own risk factors. Nov 4 filing
Investor Chat
Loading posts…
aibio